Whole-Exome Sequencing Predicting Two Extreme Phenotypes of Response to VEGF-targeted Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mRCC)

Dr. Andre P. Fay, M.D. discusses Whole-Exome Sequencing Predicting Two Extreme Phenotypes of Response to VEGF-targeted Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mRCC) at the Kidney Cancer meeting in Chicago